Regeneron Pharmaceuticals
REGN
575 hedge funds and large institutions have $42B invested in Regeneron Pharmaceuticals in 2015 Q4 according to their latest regulatory filings, with 71 funds opening new positions, 223 increasing their positions, 203 reducing their positions, and 53 closing their positions.
34% more first-time investments, than exits
New positions opened: 71 | Existing positions closed: 53
17% more capital invested
Capital invested by funds: $36.1B → $42B (+$5.98B)
8% more funds holding in top 10
Funds holding in top 10: 25 → 27 (+2)
2% more funds holding
Funds holding: 561 → 575 (+14)
10% more repeat investments, than reductions
Existing positions increased: 223 | Existing positions reduced: 203
27% less call options, than puts
Call options by funds: $714M | Put options by funds: $976M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$332M |
| 2 |
Goldman Sachs
New York
|
+$246M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$127M |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$79.2M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$71.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Sands Capital Management
Arlington,
Virginia
|
-$238M |
| 2 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$153M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$130M |
| 4 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
-$114M |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$104M |
REGN Hedge Fund Activity: Q4 2015 in Review
575 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Regeneron Pharmaceuticals (REGN) for Q4 2015, worth a combined $42B — up 17% from $36.1B a quarter earlier.
Buyers outnumbered sellers: 71 funds opened new REGN positions and 53 closed out — a net gain of 18 holders — while 223 added to existing stakes and 203 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $332M. The largest seller was Sands Capital Management, cutting an estimated $238M.
- 575 institutional investors held Regeneron Pharmaceuticals (REGN) as of Q4 2015, up from 561 in Q3 2015.
- Funds reported $42B of Regeneron Pharmaceuticals stock for Q4 2015, up 17% quarter-over-quarter.
- 71 funds opened new Regeneron Pharmaceuticals positions in Q4 2015 and 53 closed out, a net change of +18 holders.
- The largest Regeneron Pharmaceuticals buyer in Q4 2015 was Fidelity Investments, an estimated $332M added.
- The largest Regeneron Pharmaceuticals seller in Q4 2015 was Sands Capital Management, an estimated $238M sold.
Based on aggregated 13F filings for Q4 2015.